乌苯美司联合化疗用于恶性肿瘤的系统评价

发布时间：2018-03-24 02:11

  本文选题：乌苯美司　切入点：恶性肿瘤　出处：《中国药房》2017年24期

【摘要】：目的:系统评价乌苯美司联合化疗用于恶性肿瘤的疗效和安全性,为临床提供循证参考。方法:计算机检索Central、PubMed、相关期刊论文、中文科技期刊数据库、万方数据库,收集乌苯美司联合化疗(试验组)对比单纯化疗(对照组)用于恶性肿瘤的随机对照试验(RCT),筛选文献、提取资料并采用Cochrane系统评价员手册5.1.0提供的偏倚风险评价标准评价纳入研究质量,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入12项RCT,包括762例患者。Meta分析结果显示,试验组患者近期有效率[RR=1.24,95%CI(1.08,1.43),P=0.002]、生存质量(KPS)评分改善率[RR=1.69,95%CI(1.46,1.95),P0.001]显著高于对照组,胃肠道毒性发生率[RR=0.74,95%CI(0.57,0.94),P=0.02]和白细胞抑制发生率[Ⅰ°～Ⅳ°(用药≤3个月):RR=0.54,95%CI(0.37,0.79),P=0.002;Ⅲ°～Ⅳ°:RR=0.44,95%CI(0.29,0.68),P0.001]显著低于对照组,差异均有统计学意义。结论:乌苯美司联合化疗用于恶性肿瘤,可以提高患者的近期疗效,改善生存质量,降低胃肠道毒性和骨髓毒性。
[Abstract]:Objective: to evaluate the efficacy and safety of Ubenemethasone combined chemotherapy for malignant tumors and to provide evidence based reference for clinical application. Methods: a computer-based search of Centralus PubMed, Chinese Journal Full-text Database, Chinese Sci-tech Journal Database and Wanfang Database was carried out. A randomized controlled trial of Ubenemethasone combined with chemotherapy (trial group) for malignant tumors was collected and the literature was screened. The data were extracted and the bias risk evaluation criteria provided by the Cochrane system evaluator manual 5.1.0 were used to evaluate the quality of the study. The Meta analysis was carried out with Rev Man 5.3 statistical software. Results: a total of 12 RCTs were included, including 762 patients. The short-term effective rate [RRN 1.2495 CII 1.081.43 P0.002], the improvement rate of quality of life score (RRR1.6995 CI1.461.95CI1.461.95P0.001), the incidence of gastrointestinal toxicity (RR0.7495CI0.570.94FU P0.02) and the incidence of leukocyte inhibition [鈪，

本文编号：1656232